Medical Disclaimer

What goodx is — and isn't

goodx is a comparison and editorial site for GLP-1 weight loss and diabetes medications. goodx is not a pharmacy, healthcare provider, insurance company, or manufacturer. We do not sell, prescribe, dispense, or ship any medication. We connect users with licensed telehealth providers via affiliate links.

Content on goodx does not constitute medical, pharmaceutical, or healthcare advice. Reading goodx does not establish a doctor-patient relationship.

Not a substitute for professional care

Always seek the advice of a licensed healthcare provider — a physician, nurse practitioner, physician assistant, or licensed pharmacist — with any questions you may have about a medical condition, medication, dose, side effects, drug interactions, or treatment plan.

Never disregard professional medical advice or delay seeking it because of something you read on goodx. If you think you may have a medical emergency, call your doctor or 911 immediately. If you are outside the US, call your local emergency number.

GLP-1 medications carry serious risks

GLP-1 receptor agonists including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon) have known risks. These include but are not limited to:

Thyroid C-cell tumors (FDA boxed warning based on rodent studies). Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pancreatitis (acute or chronic), including some cases that have been fatal. Discontinue immediately if pancreatitis is suspected.
Gallbladder disease including cholelithiasis and cholecystitis, sometimes requiring surgery.
Acute kidney injury, especially in patients with persistent vomiting/diarrhea leading to dehydration.
Severe gastrointestinal side effects including nausea, vomiting, diarrhea, constipation, and abdominal pain. Sometimes severe enough to require hospitalization.
Hypoglycemia (low blood sugar) especially when GLP-1 is combined with insulin or sulfonylureas.
Diabetic retinopathy complications in patients with pre-existing eye disease.
Hypersensitivity reactions including angioedema and anaphylaxis.
Suicidal ideation (under FDA investigation as of 2024–2026).
Ileus / gastroparesis (slowed or paralyzed stomach emptying) — relevant for surgery and anesthesia planning.

These medications are not appropriate for everyone. Pregnancy, planned pregnancy, and breastfeeding are contraindications for most GLP-1s. Discuss your full medical history with your physician before starting any GLP-1 medication.

Compounded GLP-1 medications

Compounded versions of GLP-1 medications (compounded semaglutide, compounded tirzepatide, compounded liraglutide) are not FDA-approved formulations. The FDA does not review compounded medications for safety, efficacy, or manufacturing quality. Critical points to understand:

Quality varies by compounding pharmacy. Verify the pharmacy is state-licensed (503A) or FDA-registered (503B).
The FDA has issued warning letters to multiple telehealth providers marketing compounded GLP-1 medications in 2024–2026.
Following the official drug shortage being resolved (semaglutide April 2025, tirzepatide March 2025), the legal basis for compounded GLP-1 has narrowed.
Some compounded GLP-1 products contain ingredients (e.g., B12, L-carnitine) added to attempt to fall outside FDA compounding restrictions — these claims are contested by the FDA.
Adverse event reports for compounded GLP-1 have led to FDA warnings about dosing errors and contamination.

If you currently use or are considering compounded GLP-1, discuss the risks with a licensed healthcare provider.

Off-label use

Some GLP-1 medications discussed on goodx are FDA-approved for type 2 diabetes but commonly prescribed off-label for weight loss (e.g., Ozempic, Mounjaro). Off-label prescribing is legal but carries additional considerations including insurance coverage and informed consent. Discuss off-label use with your prescribing provider.

Pricing and availability are subject to change

Pricing, availability, FDA approval status, and regulatory information shown on goodx are reference estimates and may change without notice. We make reasonable effort to keep information current but cannot guarantee accuracy at any given moment. Always verify with the telehealth provider, pharmacy, or insurer directly before making purchase decisions.

AI-generated content

If goodx provides any AI-generated educational content, it is labeled as such. AI-generated content is trained on publicly available data including FDA labels and peer-reviewed literature as of the model's training cutoff. AI content is not a substitute for a clinician's judgment. Verify any claim against an authoritative source and discuss with your provider.

Not insurance

goodx is NOT insurance. It is not a prescription discount card, not a pharmacy, not a healthcare plan, and not a Medicaid/Medicare program. Insurance coverage estimates on the Site are educational references based on common plan structures; your specific plan may differ.

State-specific limitations

Telehealth practice rules and pharmacy advertising laws vary by US state. Some states require synchronous video visits for new GLP-1 prescriptions; some require pre-existing patient relationships; some Medicaid programs do not cover GLP-1 for weight loss. State-specific information on goodx is reference-only — verify with your state medical board and the telehealth provider.

Contact

If you have questions about this disclaimer or content on goodx, email [email protected]. For medical emergencies, do not email us — call 911 or your local emergency number.